Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Overcoming Endocrine Resistance in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 396
- Registration Number
- NCT02394496
- Locations
- 🇮🇹
Ospedale Sacro Cuore - Don Calabria U.O.C. Oncologia Medica, Negrar, Verona, Italy
🇮🇹Azienda Ospedaliera Treviglio-Caravaggio U.O. Oncologia Medica, Treviglio, Bergamo, Italy
🇮🇹Presidio Ospedaliero di Vallo della Lucania U.O. Oncologia Medica, Vallo Della Lucania, Salerno, Italy
Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT02342587
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT02338245
- Locations
- 🇵🇭
Philippines, Dasmarinas, Philippines
🇸🇬Singapore, Singapore, Singapore
🇦🇺Australia, Western Australia, Australia
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT02294786
- Locations
- 🇬🇧
Novartis Investigative Site, Romford, United Kingdom
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 154
- Registration Number
- NCT02238509
- Locations
- 🇮🇹
A.O.U. Ospedali Riuniti Umberto I, Ancona, Italy
🇮🇹Ospedale Centrale di Bolzano, Bolzano, Italy
🇮🇹Humanitas Centro Catanese di Oncologia, Catania, Italy
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02230553
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT02213042
- Locations
- 🇹🇭
Novartis Investigative Site, Phitsanulok, Thailand
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT02101905
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 32
- Registration Number
- NCT02073487
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
🇺🇸Houston Methodist Hospital Willowbrook, Houston, Texas, United States
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Jenny C. Chang, MD
- Target Recruit Count
- 24
- Registration Number
- NCT02073916
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.